Alternatives to a routine follow-up visit for early medical abortion

Obstetrics and Gynecology

Volumn 115, Issue 2 PART 1, 2010, Pages 264-272

  Clark, Wesley ^b   Bracken, Hillary ^a   Tanenhaus, Jini ^b   Schweikert, Suzanne ^b   Lichtenberg, E Steve ^b   Winikoff, Beverly ^b  

^a GYNUITY HEALTH PROJECTS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MIFEPRISTONE; MISOPROSTOL; ABORTIVE AGENT;

ABORTION; ADULT; ARTICLE; CLINICAL TRIAL; CURETTAGE; ECHOGRAPHY; FEMALE; GYNECOLOGICAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREGNANCY TEST; PRIORITY JOURNAL; FIRST TRIMESTER PREGNANCY; INDUCED ABORTION; PATIENT CARE; PREGNANCY; UTERUS;

ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; ADULT; CONTINUITY OF PATIENT CARE; FEMALE; HUMANS; MIFEPRISTONE; MISOPROSTOL; PREGNANCY; PREGNANCY TRIMESTER, FIRST; UTERUS;

EID: 76549084135     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181c996f3     Document Type: Article

References (13)

1. National Abortion Federation. 2009 Clinical Policy Guidelines. Washington, DC: NAF; 2009. Available at: http://www.prochoice.org/pubs-research/ publications/downloads/professional-education/CPG2009.pdf. Retrieved May 27, 2009.
2. Mifeprex Tablets [package insert]. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/label/2000/20787lbl.htm. Retrieved December 17, 2008.
3. Jones RK, Henshaw SK. Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden. Per-spect Sex Reprod Health 2002;34:154-61.
4. Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol 2003;109: 190-5.
5. Pymar HC, Creinin MD, Schwartz JL. Mifepristone followed on the same day by vaginal misoprostol for early abortion. Contraception 2001;64:87-92.
6. Rossi B, Creinin MD, Meyn LA. Ability of the clinician and patient to predict the outcome of mifepristone and misoprostol medical abortion. Contraception 2004;70:313-7.
7. Grossman D, Berdichevsky K, Larrea F, Beltran J. Accuracy of a semi-quantitative urine pregnancy test compared to serum beta-hCG measurement: a possible screening tool for ongoing pregnancy after medication abortion. Contraception 2007;76: 101-4.
8. Godfrey EM, Anderson A, Fielding SL, Meyn L, Creinin MD. Clinical utility of urine pregnancy assays to determine medical abortion outcome is limited. Contraception 2007;75:378-82.
9. Winikoff B. Acceptability of medical abortion in early pregnancy. Fam Plann Perspect 1995;27:142-8, 185.
10. Newhall EP, Winikoff B. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions. Am J Obstet Gynecol 2000;183(suppl):S44-53.
11. Hoffman JR, Wolfson AB, Todd K, Mower WR. Selective cervical spine radiography in blunt trauma: methodology of the National Emergency X-Radiography Utilization Study (NEXUS). Ann Emerg Med 1998;32:461-9.
12. Hoffman JR, Mower WR, Wolfson AB, Todd KH, Zucker MI. Validity of a set of clinical criteria to rule out injury to the cervical spine in patients with blunt trauma. National Emergency X-Radiography Utilization Study Group. N Engl J Med 2000;343:94-9.
13. Gynuity Health Projects. Exploring semi-quantitative pregnancy tests and their impact on reproductive health service provision. NCT 00812890. Available at: http://clinicaltrials.gov/ct2/show/NCT00812890. Retrieved May 27, 2009.